Featured Entrepreneurs

Since 2010, MassChallenge has accelerated 1,975 startups that have raised more than $4.3 billion in funding, generated more than $2.5 billion in revenue, and created more than 121,000 total jobs. 

Our startups

Be inspired. Search our startups.


We have a nontoxic short duration breast cancer treatment. Our main drug is an intracellular cancer killing peptide eradicating 100% of ALL breast cancer cells in 96 hours in vitro and 91% of ALL breast cancer cells within 14 days in vivo. While our cancer targeting Cell Penetrating Peptide (CPP) delivers our cancer killing cargo with no healthy cell interaction. Our CPP can also be conjugated to increase efficacy by 4-6x and decrease toxicity by 6-20x of currently approved FDA chemotherapeutics
We have a revolutionary nontoxic short duration breast cancer treatment. Offering a higher quality of life compared to current treatments.

Connect with MicroQuin


2018 Silver Boston

Sub industry

Therapeutics (Pharma / Biotech)


MassChallenge strengthens the global innovation ecosystem by accelerating high-potential startups across all industries, from anywhere in the world.